Kailera trades below its April IPO price as data slips to 2027 and beyond

Kailera Therapeutics, a clinical-stage company built around China-origin obesity drugs, closed recently at $18.51 per share, giving it a market capitalization of about $2.40 billion — down roughly 29% since its shares began trading in April ^[1]. The company holds $1.17 billion in cash and marketable securities and says that money should last into mid-2028 ^[1].

Kailera has no approved products and no product revenue. Its lead drug, ribupatide injection, is a GLP-1/GIP dual agonist being tested in a global Phase 3 program called KaiNETIC that has enrolled more than 4,700 participants ^[1][2]. That trial's data are not expected until 2028 ^[1][2]. A smaller U.S. Phase 2b trial testing higher doses of ribupatide, with 264 participants, is fully enrolled and expected to report data in mid-2027 ^[1]. Two other pipeline drugs, KAI-7535 and the tri-agonist KAI-4729, are expected to post Phase 2 and Phase 1 data, respectively, sometime in 2027 ^[1].

The stock's slide has been volatile. In late August, shares fell 12.5% in a single session to $16.21, leaving the company's roughly $2.10 billion market value only about $930 million above its cash holdings — a gap that reflects how investors are pricing an unproven pipeline ^[2]. Kailera priced its April IPO at $16 a share and opened trading at $26 amid strong demand for obesity-drug assets ^[2]. Second-quarter research and development spending reached $101.1 million, and the net loss widened to $111.3 million from $28.9 million a year earlier ^[1][2].

Kailera's relationship with Chinese drugmaker Jiangsu Hengrui Pharmaceuticals shapes both its opportunity and its costs. Hengrui holds about 19.9% of Kailera's shares and stands to collect up to $5.725 billion in commercial milestone payments plus royalties if Kailera's drugs succeed in the U.S., Europe and Japan — the territory covered by the licensing deal, which excludes mainland China, Hong Kong, Macau and Taiwan ^[1]. In a related China trial, KAI-7535 produced up to 11.1% mean weight loss, but nausea affected about 70% of treated patients and vomiting affected more than 65%, according to July data — a tolerability profile Kailera is now trying to improve in its global Phase 2 study through lower starting doses and slower dose increases ^[2].

Why it matters for patients

None of Kailera's drugs are close to reaching pharmacies. The company's key clinical readouts are staggered through 2027 and 2028, meaning any potential new obesity treatment from this pipeline is likely years away from an FDA decision, let alone availability ^[1][2]. For people currently using or considering approved GLP-1 drugs such as Wegovy, Zepbound, Ozempic or Mounjaro, this timeline does not change what is on the market today. It may, however, affect how much competition — and potential downward pressure on prices — patients could see in the U.S. market several years out, depending on whether Kailera's data hold up.

The tolerability data on KAI-7535, with high rates of nausea and vomiting in a China trial, is a reminder that gastrointestinal side effects remain a central challenge across this drug class generally, not just for Kailera ^[2]. Kailera is adjusting its dosing approach in response, and whether that works will only become clear when 2027 results arrive ^[2].

What happens next

Several dated milestones are ahead. Mid-2027 is expected to bring Phase 2b data on high-dose ribupatide injection ^[1][2]. Also in 2027, KAI-7535 Phase 2 results and KAI-4729 Phase 1 data are expected, along with the planned start of global Phase 3 testing for an oral version of ribupatide in the first half of 2027 ^[1][2]. The largest event, the global KaiNETIC Phase 3 readout for ribupatide injection, is expected in 2028 — the same year Kailera's current cash runway is projected to run out ^[1][2].